Invivyd, Inc. (IVVD) Q1 2026 Earnings Call Transcript
Invivyd Q1 Earnings Call Highlights
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights
Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination
Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit
Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody Candidate Transcript
Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program
Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Invivyd, Inc. (NASDAQ:IVVD) Receives $8.00 Consensus Target Price from Brokerages
Invivyd Announces Presentation at the World Vaccine Congress Washington
Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching
Invivyd, Inc. (NASDAQ:IVVD) Receives $8.00 Consensus Target Price from Brokerages
Invivyd Q4 Earnings Call Highlights
Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
Invivyd (NASDAQ:IVVD) Shares Up 10.6% – What’s Next?
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
Here Are Monday’s Top Wall Street Analyst Research Calls: BlackSky Technology, Cummins, Lamb Watson, Ollie’s Bargain Outlet, Sealed Air, Volaris, and More
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference
Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness
Invivyd: Maintaining Hold Rating With VYD2311 Alternative To Covid-19 Vaccination
Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants
Invivyd Announces Proposed Public Offering of Common Stock
Invivyd (NASDAQ:IVVD) Reaches New 1-Year High – Time to Buy?
Invivyd Target of Unusually High Options Trading (NASDAQ:IVVD)
Invivyd, Inc. (IVVD) Q3 2025 Earnings Call Transcript
Invivyd, Inc. (IVVD) Reports Q3 Loss, Lags Revenue Estimates
Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025
Invivyd, Inc. (IVVD) Discusses REVOLUTION Clinical Program and Development of VYD2311 Antibody for COVID Prevention Transcript
Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
Invivyd Appoints Paul B. Bolno, M.D.
Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer
SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025